Shares of Chemed Co. (NYSE:CHE) have been assigned an average rating of “Hold” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $236.00.
A number of equities analysts have commented on CHE shares. Oppenheimer increased their target price on Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, October 27th. Zacks Investment Research cut Chemed from a “buy” rating to a “hold” rating in a report on Wednesday, September 13th. Royal Bank of Canada increased their target price on Chemed to $232.00 and gave the company a “sector perform” rating in a report on Tuesday, October 31st. KeyCorp reissued a “hold” rating on shares of Chemed in a report on Friday, October 27th. Finally, ValuEngine cut Chemed from a “buy” rating to a “hold” rating in a report on Friday, December 1st.
In other Chemed news, EVP Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $228.45, for a total transaction of $228,450.00. Following the completion of the sale, the executive vice president now owns 36,809 shares of the company’s stock, valued at $8,409,016.05. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Patrick P. Grace sold 500 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $201.48, for a total value of $100,740.00. Following the sale, the director now directly owns 4,515 shares of the company’s stock, valued at approximately $909,682.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,179 shares of company stock valued at $10,729,699. Insiders own 4.90% of the company’s stock.
Chemed (NYSE:CHE) opened at $242.41 on Friday. Chemed has a fifty-two week low of $155.82 and a fifty-two week high of $251.00. The company has a market capitalization of $3,847.65, a P/E ratio of 53.87, a price-to-earnings-growth ratio of 5.09 and a beta of 1.16. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15.
Chemed (NYSE:CHE) last announced its earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.15. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The business had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. During the same quarter in the prior year, the firm earned $1.73 earnings per share. The business’s revenue was up 6.3% compared to the same quarter last year. equities research analysts expect that Chemed will post 4.73 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Monday, December 4th. Investors of record on Monday, November 13th were issued a $0.28 dividend. The ex-dividend date was Friday, November 10th. This represents a $1.12 annualized dividend and a dividend yield of 0.46%. Chemed’s dividend payout ratio is presently 24.89%.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.